DVAX Dynavax Technologies Corporation

XNAS 15.49 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

DVAX $15.49 —

What changed

Recent filings, trades and moves
Key stats
$15.49
52-Week Range
$10.63 – $15.73
YTD
+0.75%
IV Rank (30D)
28.66
Straddle Price
$3.08
P/C Vol Ratio (Mar 20 expiry)
3.63
Market Cap
$1.8B
Open
$15.49
Day Range
$15.49 – $15.50
Volume
7,106,122
Prev Close
$15.50
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$1.8B
Employees
405
List Date
2004-02-19
CIK
0001029142
Last Earnings
Nov 5 after close · +6.7% vs ±12.4% expected
Headquarters
Emeryville, CA
Homepage
https://www.dynavax.com

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adap…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
Insufficient price history — listed 8299 days ago. Seasonality patterns need at least one full year of data.
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $15.56
SMA 50: $13.77
SMA 200: $11.21
Current: $15.50
EMA 12: $15.48
EMA 26: $15.09
MACD: 0.3920 | Signal: -0.1481
BULLISH
ADX (14): 59.80
STRONG TREND
+DI: 46.49
−DI: 12.69

Momentum Oscillators

RSI (14): 76.00
OVERBOUGHT
Stoch %K: 15.94
Stoch %D: 15.94
Williams %R: -82.61

Volume & Volatility

BB Upper: $15.73
BB Lower: $15.39
NEUTRAL
OBV: 82,221,490
Vol SMA 20: 2,892,154
Vol ROC: 301.21%
ATR: $0.11
True Range: $0.01
HV 20: 7.9%
HV 30: 6.5%
HV 60: 68.9%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-02-12T00:00:00 – 2026-02-09T00:00:00
AI Analysis

LLM Stock Analysis Report

Executive Summary Overall Assessment: NEUTRAL (Confidence Level: 6/10)

Key Drivers:

  • Strong technical momentum signals
  • Low volatility compared to market
  • Recent news headline regarding Sanofi's acquisition of Dynavax Technologies Corporation (DVAX) has a neutral sentiment

Primary Risks:

  • Overbought RSI and Stochastic Oscillators indicating potential reversal
  • High IV rank suggesting historical volatility is high, which may lead to increased price swings

Investment Thesis: The stock is currently experiencing strong technical momentum, with multiple indicators aligned. However, the recent news headline regarding the acquisition has a neutral sentiment, which may not have significant impact on the stock's price movement.

Recent News Sentiment Impact: The recent news headline has a neutral sentiment, which suggests that it may not have a significant impact on the stock's price movement. The neutral sentiment also indicates that the market is not strongly reacting to this news, which may be a sign of caution for investors.

Technical Analysis

  • Trend Direction: Short-term: UPTREND (1-4 weeks), Medium-term: UPTREND (1-3 months), Long-term: UPTREND (3-12 months)
  • Support/Resistance Levels: Key price levels from moving averages and technical patterns:
    • Upper Bollinger Band: $14.06
    • Middle Band: $11.37
    • Lower Band: $8.68
  • Momentum Signals:
    • RSI (14): 89.44 (overbought)
    • MACD: 0.66 / Signal: 0.44 / Histogram: 0.22 (bullish)
  • Volume Analysis: Volume trends and institutional interest signals:
    • On-Balance Volume (OBV): 38323921.00
    • Volume Rate of Change: 388.79%

News & Sentiment Analysis

  • Recent Headlines Summary: Key themes from last 10 news articles:
    • Acquisition by Sanofi has a neutral sentiment
    • Other recent news headlines have mixed sentiments, but none are strongly bearish or bullish
  • Sentiment Assessment: Aggregate news sentiment: NEUTRAL (60% positive, 20% negative, 20% neutral)
  • Catalyst Identification: Upcoming events:
    • Earnings release on [Date]
  • Market Narrative: News aligns with technical signals, suggesting a potential continuation of the uptrend

Risk & Volatility Assessment

  • Beta Interpretation: Risk relative to market (beta = 0.54): Low volatility - stock moves less than market
  • Volatility Regime: Current vs historical volatility levels:
    • Average True Range (ATR): $0.53
    • True Range: $0.04
  • Options Market Signals: IV rank, put/call ratios, unusual activity:
    • IV Rank: 76.2% (High)
    • Put/Call Volume Ratio: 0.43 (Bullish sentiment)

Market Context & Positioning

  • Sector Performance: Relative strength vs sector/market:
    • Sector: Biotechnology
    • Market: S&P 500
  • Institutional Activity: Volume patterns suggesting institutional interest:
    • Institutional ownership: [Data]
  • Correlation Analysis: How stock moves relative to market (R-squared interpretation):
    • R-squared value: [Data]

Key Levels & Action Items

  • Critical Price Levels: Support/resistance to monitor:
    • Upper Bollinger Band: $14.06
    • Middle Band: $11.37
    • Lower Band: $8.68
  • Breakout/Breakdown Levels: Technical levels that could trigger significant moves:
    • SMA 20: $11.37
    • EMA 12: $12.21
  • Time-Sensitive Catalysts: Earnings dates, FDA approvals, product launches:
    • Earnings release on [Date]
  • Risk Management: Stop-loss levels and position sizing considerations:
    • Stop-loss at $13.50 (5% below current price)
    • Position sizing: 2-3% of portfolio

Note: The analysis is based on the provided data, and any changes or updates to the data may affect the assessment.

Generated
Earnings History
17 of 21 under expected move
Avg Expected Move
12.18%
Avg Actual Move
6.42%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2021-02-25 After-Close 23.28% 7.23% 0.31x Within
2021-05-06 After-Close 15.20% 10.47% 0.69x Within
2021-08-04 After-Close 16.70% 4.55% 0.27x Within
2021-11-04 After-Close 17.87% 22.16% 1.24x Exceeded
2022-02-28 After-Close 18.68% 0.41% 0.02x Within
2022-05-05 After-Close 12.10% 2.05% 0.17x Within
2022-08-04 After-Close 12.90% 16.11% 1.25x Exceeded
2022-11-03 After-Close 10.92% 12.62% 1.16x Exceeded
2023-01-09 After-Close 9.25% 3.99% 0.43x Within
2023-02-23 After-Close 7.24% 3.81% 0.53x Within
2023-05-02 After-Close 8.73% 6.89% 0.79x Within
2023-08-03 After-Close 9.78% 8.29% 0.85x Within
2023-11-02 After-Close 9.95% 1.07% 0.11x Within
2024-01-08 After-Close 6.08% 0.43% 0.07x Within
2024-02-22 After-Close 11.50% 2.49% 0.22x Within
2024-05-08 After-Close 9.27% 5.49% 0.59x Within
2024-08-06 Pre-Market 10.18% 0.20% 0.02x Within
2024-11-07 Pre-Market 10.37% 2.20% 0.21x Within
2025-05-06 After-Close 7.10% 10.99% 1.55x Exceeded
2025-08-07 After-Close 16.27% 6.60% 0.41x Within
2025-11-05 After-Close 12.38% 6.70% 0.54x Within

Earnings calendar: this week’s reports with expected vs actual moves →

DVAX Options Activity & IV Rank

DVAX IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 52.6%
7-DTE IV: 122.5%
Expected Move: $3.08
7-DTE Move: $2.50
Days to Exp: 39 (2026-03-20)

Options Flow · Mar 20 expiry

Call Volume: 223
Put Volume: 809
P/C Volume: 3.628
BEARISH
Call OI: 318
Put OI: 821
P/C OI: 2.582
Total OI: 1,139

ATM Options Pricing

ATM Call: $0.57
ATM Put: $2.50
Call %: 3.7%
Put %: 16.1%

Chain Summary

Chain Volume: 4,013
Chain OI: 15,327
Last Updated: 2/9/2026
Spread Scanner
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Scanning bull put, bear call, iron condor and calendar spreads…

Dealer Positioning
LOW γ vs HISTORY

Estimated net dealer gamma is at the 3rd percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
3%
vs own history
GEX tilt
-0.65
OI-weighted, today
Vanna tilt
+0.93
δ-sensitivity to IV
Charm tilt
-0.95
δ-decay vs time
Vanna tilt +0.93: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.95: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 22 ATM contracts, 10k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
as of Feb 9 · No data
30 DTE / 10d —
— pts EXTREME
as of Feb 9 · No data

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Loading the implied volatility surface…

Volatility Smile

Loading the implied volatility smile…

IV Rank (7 DTE)44.8MediumFeb 9
IV Rank (30 DTE)28.7MediumFeb 9

Embed DVAX IV rank

DVAX's 30-day IV rank (90 sessions) with its 52-week rank, at-the-money IV and a 90-session trend. Updates after each close. Paste the code into any web page or blog post. Email newsletters drop iframes, so link to the page there.

Theme
Preview
Straddle Price (30 DTE)$3.08Feb 9
Beta Analysis
Insufficient price history — listed 8299 days ago. Beta and correlation vs SPY require ~1 year of daily returns to be statistically meaningful.

DVAX Institutional Ownership (13F)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

# Filer Shares Value % of Total % of Float Period
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period

DVAX Insider Trading (Form 4)

Latest: 2026-02-11
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-02-11 Deep Track Biotechnology Master Fund, Ltd. 10%+ Owner U −15,726,349 — EDGAR
2026-02-10 Emilio Emini Director Disp (D) −10,075 — EDGAR
2026-02-10 Scott Dunseth Myers Director Mixed
Disp −31,204 · U −3,800
 −35,004 — EDGAR
2026-02-10 Joseph Anthony Metzinger VP, Chief Accounting Officer U −7,129 — EDGAR
2026-02-10 David F Novack President & COO Mixed
Grant +124,224 · Disp −124,224 · U −63,334
 −63,334 — EDGAR
2026-02-10 Lauren P Silvernail Director Disp (D) −10,075 — EDGAR
2026-02-10 Elaine D Sun Director Disp (D) −29,865 — EDGAR
2026-02-10 Ryan Spencer CEO and Director Mixed
Grant +301,000 · U −379,620 · Disp −301,000
 −379,620 — EDGAR
2026-02-10 Daniel L Kisner Director Mixed
Disp −21,829 · U −1,500
 −23,329 — EDGAR
2026-02-10 Brent MacGregor Director Disp (D) −21,829 — EDGAR
2026-02-10 Francis Cano Director Disp (D) −42,663 — EDGAR
2026-02-10 John L Slebir SVP General Counsel Mixed
U −69,634 · Grant +92,424 · Disp −92,424
 −69,634 — EDGAR
2026-02-10 Kelly MacDonald SVP and CFO Mixed
Disp −88,854 · U −60,204 · Grant +88,854
 −60,204 — EDGAR
2026-01-20 David F Novack President & COO Mixed
Exer +114,000 · Sell −114,000
 — $12.73 -$662.7K EDGAR
2025-12-29 John L Slebir SVP General Counsel Mixed
Exer +30,808 · Tax −32,502 · Grant +33,750
 +32,056 $15.38 -$499.9K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

DVAX Insider Holdings

5 insiders · @ $15.50
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Ryan Spencer CEO and Director 136,000 $2.11M -$1.13M 21 2026-02-10
2 Robert Janssen SVP and CMO 81,526 $1.26M -$5.42M 54 2025-02-20
3 Peter R. Paradiso Director 24,829 $384.8K $0 6 2025-06-13
4 Justin Burgess VP Finance & CAO 6,666 $103.3K -$1.77M 19 2025-02-12
5 Daniel L Kisner Director 1,500 $23.2K $10.8K 20 2026-02-10
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

DVAX Board & Officers

As of SEC filings through Feb 11, 2026
Changes in the last 10 years (44)
Feb 11, 2026Deep Track Capital, LP reported in an SEC filing no longer being a 10% owner
Feb 11, 2026Deep Track Biotechnology Master Fund, Ltd. reported in an SEC filing no longer being a 10% owner
Feb 11, 2026David Kroin reported in an SEC filing no longer being a 10% owner
Feb 10, 2026The company announced the departure of Peter R. Paradiso from the board in an SEC filing
Feb 10, 2026Scott Dunseth Myers reported in an SEC filing no longer being a director
Feb 10, 2026Ryan Spencer reported in an SEC filing no longer being a director
Feb 10, 2026Ryan Spencer reported in an SEC filing no longer being CEO and Director
Feb 10, 2026Lauren P Silvernail reported in an SEC filing no longer being a director
Feb 10, 2026Kelly MacDonald reported in an SEC filing no longer being SVP and CFO
Feb 10, 2026Joseph Anthony Metzinger reported in an SEC filing no longer being VP, Chief Accounting Officer
Feb 10, 2026John L Slebir reported in an SEC filing no longer being SVP General Counsel
Feb 10, 2026Francis Cano reported in an SEC filing no longer being a director
Feb 10, 2026Emilio Emini reported in an SEC filing no longer being a director
Feb 10, 2026Elaine D Sun reported in an SEC filing no longer being a director
Feb 10, 2026David F Novack reported in an SEC filing no longer being President & COO
Feb 10, 2026Daniel L Kisner reported in an SEC filing no longer being a director
Feb 10, 2026Brent MacGregor reported in an SEC filing no longer being a director
May 12, 2025Joseph Anthony Metzinger became VP, Chief Accounting Officer
Feb 3, 2025Lauren P Silvernail became a director
Feb 3, 2025Emilio Emini became a director
Not reported recently (11)
  • Robert Janssen · Last reported as SVP and CMO in an SEC filing dated Feb 20, 2025
  • Justin Burgess · Last reported as VP Finance & CAO in an SEC filing dated Feb 12, 2025
  • Natale S Ricciardi · Last reported as a director in an SEC filing dated May 27, 2022
  • Michael S Ostrach · Last reported as Senior Vice President in an SEC filing dated Feb 5, 2021
  • Arnold L Oronsky · Last reported as a director in an SEC filing dated May 29, 2020
  • David Louis Johnson · Last reported as Vice President in an SEC filing dated Mar 16, 2020
  • Robert Coffman · Last reported as Senior Vice President in an SEC filing dated Jun 4, 2019
  • Eddie Gray · Last reported as a director in an SEC filing dated Jun 4, 2019
  • Dennis Carson · Last reported as a director in an SEC filing dated May 31, 2019
  • Laura Brege · Last reported as a director in an SEC filing dated May 31, 2019
  • Stanley A Plotkin · Last reported as a director in an SEC filing dated Jun 2, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

DVAX Proposed Insider Sales (Form 144)

Latest: 2026-01-15
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-01-15 DAVID NOVACK Officer 114,000 $1.78M 2026-01-15 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2025-12-29 DAVID NOVACK Officer 30,000 $464.7K 2025-12-24 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2025-03-24 DAVID NOVACK Officer 10,000 $140.0K 2025-03-24 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2025-03-18 DAVID NOVACK Officer 14,020 $190.4K 2025-03-18 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2025-03-07 DAVID NOVACK Officer 32,764 $471.4K 2025-03-07 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2024-03-01 Burgess Justin Officer 20,526 $262.4K 2024-03-01 Morgan Stanley Smith Barney LLC … — EDGAR
2024-01-04 Janssen Robert Officer 82,144 $1.29M 2024-01-04 Pershing Advisor Solutions LLC, … 10b5-1 EDGAR
2024-01-02 DAVID NOVACK Officer 9,000 $130.0K 2024-01-02 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2023-12-01 DAVID NOVACK Officer 20,000 $271.1K 2023-12-01 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2023-11-17 Andrew A. F. Hack Former Director 81,250 $1.10M 2023-11-17 Morgan Stanley Smith Barney LLC … — EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-0.37
TTM Revenue
$330.51M
TTM Net Income
$-43.40M
TTM Op. Cash Flow
$90.63M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q3 '252025-09-30$94.88M$26.93M$0.21$33.83M
Q2 '252025-06-30$95.44M$18.72M$0.14$23.43M
Q1 '252025-03-31$68.16M$-96.10M$-0.77$-19.64M
Q4 '242024-12-31$72.03M$7.05M$0.05$53.01M
Q3 '242024-09-30$80.63M$17.59M$0.12$19.47M
Q2 '242024-06-30$73.80M$11.39M$0.08$10.71M
Q1 '242024-03-31$50.79M$-8.72M$-0.07$-16.68M
Q4 '232023-12-31$55.60M$219.00K$0.00$13.77M
Q3 '232023-09-30$69.51M$14.29M$0.10$31.13M
Q2 '232023-06-30$60.25M$3.43M$0.03$28.05M
Q1 '232023-03-31$46.92M$-24.33M$-0.19$27.62M
Q4 '222022-12-31$184.49M$67.45M$0.46$34.95M
Q3 2025 • period ending 2025-09-30 • filed 2025-11-05
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
—
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-8.1%
ROA
-4.6%
Div Yield
—
FCF Yield
—
Debt/Equity
0.41
Current Ratio
—
Market Cap
$0.00
as of 2026-02-10

DVAX vs Peers

Related companies, largest first
Company Market cap P/E Revenue growth YTD IV rank
LLY Eli Lilly & Co. $1.21T 45.8 +45.5% +30.7% 27
JNJ Johnson & Johnson $664.9B 42.8 +7.8% +36.1% 54
ABBV ABBVIE INC. $514.9B 50.5 +10.7% +27.9% 30
MRK Merck & Co., Inc. $361.7B 153.4 +4.9% +39.7% 44
NVS Novartis AG $307.0B — — +18.2% 36
AZN AstraZeneca PLC $289.1B — — +106.8% 0
ABT Abbott Laboratories $190.4B 40.9 +10.0% −11.0% 20
NVO Novo-Nordisk A/S $177.7B — — −21.0% 15
DVAX Dynavax Technologies Corporation $1.8B — +26.7% +0.8% —
Peer median $334.4B 45.8 +10.0% +29.3% 28

P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.

Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
9.79M
SI % of Float
8.69%
Days to Cover
5.22
Short Vol Ratio
36.7%
Free Float
112.71M
Float %
96.1%
Short interest 2026-01-30 • Short volume 2026-02-09 • Float 2025-12-02